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Background: Sudden cardiac arrest (CA) represents a signifi cant cause of death worldwide. 
Post-CA mortality remains high, although a steady decline in mortality rates has occurred 
since the implementation of the ‘chain of survival’. Th is concept refers to a specifi c and 
properly timed series of actions directed towards improving post-CA outcomes. In-
hospital patients carry a particularly high risk of CA, both on the general ward and in the 
intensive care unit (ICU). With over 10,000 CAs occurring daily globally, undoubtedly CA 
has a signifi cant socioeconomic impact. However, data on in-hospital CA (IHCA) and CA-
related healthcare costs in Finland, as well as globally, remain limited. Critically ill patients 
are oft en admitted to ICUs to undergo complex treatments that may or may not infl uence 
patient outcomes. Yet, changes in treatment intensity can potentially refl ect a specifi c 
patient’s clinical condition and carry additional prognostic value.
Aims: Th is study aimed to systematically review published literature on in-ICU CA (ICU-
CA), to investigate outcomes and healthcare-associated costs for CA patients treated 
within Finnish ICUs and to explore the individual eff ects of early treatment intensity and 
cardiopulmonary resuscitation on hospital mortality amongst Finnish ICU patients.
Methods: Th is study consisted of a systematic review of the published literature (study I) 
summarising scientifi c evidence on CA in critically ill patients, and three original substudies 
on patients treated in Finnish ICUs between 2003 and 2013. Th e data for the substudies 
were acquired from the databases of the Finnish Intensive Care Consortium (FICC), the 
Social Insurance Institution of Finland (SII) and the Finnish Population Register Centre. 
Two of the substudies included patients from all Finnish ICUs, whilst one substudy 
consisted of patients from a single tertiary teaching hospital. Study endpoints were ICU-
CA incidence and hospital mortality (study II), the association of treatment intensity and 
hospital mortality (study III) and survival and neurological outcome at one year aft er CA 
(study IV). Cost data comprised index hospitalisation expenses, rehabilitation costs and 
social security costs up to one year aft er CA. Eff ective cost per one-year survivor refl ected 
the economic impact of CA, calculated as the sum of the total of healthcare costs divided by 
the number of survivors.
Results: Across substudies, patient population size varied from n = 1024 to n = 164,255. 
A systematic review of the literature analysed 18 studies published between 1990 and 
2013. Most of the reviewed publications were single-centre and retrospective. Incidence 
and the outcome of ICU-CA in the published literature varied widely depending upon 
the study population and settings. In Finland, there were 29 ICU-CAs for every 1000 ICU 
admissions. ICU-CA hospital mortality reached 56%. Amongst CA patients treated in a 
tertiary teaching hospital ICUs, 58% of out-of-hospital CA (OHCA) patients, 41% of IHCA 
patients and 39% of ICU-CA patients remained alive at one year following the initial arrest. 
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Amongst all one-year survivors, 88% to 94% had a favourable neurological outcome. Th e 
eff ective cost, expressed in 2013 euro, was €94,688 for a one-year survivor and €102,722 
for a one-year survivor with a favourable neurological outcome. A CA event and poor 
preadmission functional status, defi ned as full dependency in self-care, were associated 
with a similar increase in the risk of hospital mortality. An increase in the intensity of early 
treatment associated with a higher risk of in-hospital death, particularly amongst patients 
with an initially low mortality risk.
Conclusions: Th e incidence of ICU-CA amongst Finnish critically ill patients was higher 
and mortality was lower than previously published fi ndings. Amongst ICU-treated CA 
patients, the eff ective costs for one-year survivors were comparable to or lower than costs 
for ICU-treated patients with acute renal failure and critically ill cancer patients, healthcare 
expenditures considered generally acceptable. Th e increase in the risk of in-hospital death 
due to CA was comparable in magnitude to a poor preadmission functional status. Early 
increase in treatment intensity can serve as an additional warning sign of deterioration in 
Finnish critically ill patients.
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TIIVISTELM
Äkillinen sydämenpysähdys on merkittävä kuolinsyy maailmanlaajuisesti. Erityisen 
korkea sydämenpysähdyksen riski on sairaalahoidossa olevilla potilailla sekä 
tavallisella vuodeosastolla että myös teho-osastolla. Maailmassa tapahtuu noin 10000 
sydämenpysähdystä päivittäin, näin ollen sydämenpysähdyksen taloudellinen vaikutus on 
kiistaton. 
Tämän tutkimuksen tavoitteina oli arvioida systemaattisesti julkaistua kirjallisuutta 
tehohoidossa olevien potilaiden sydämenpysähdyksestä, selvittää ennuste ja hoitoon 
liittyvät kustannukset suomalaisilla teho-osastoilla hoidetuilla sydämenpysähdyspotilailla 
ja arvioida tehohoitopotilaiden hoitointensiteetin nousun ja tehohoidon aikaisen 
sydämenpysähdyksen itsenäiset vaikutukset potilaiden kuolemanriskiin pohjautuen 
Suomen Tehohoitokonsortion, Väestörekisterikeskuksen ja Kansaneläkelaitoksen 
potilastietokantoihin.
Systemaattisen kirjallisuuskatsauksen perusteella todettiin, että suurin osa teho-
osastoilla tapahtuvaa sydämenpysähdystä käsittelevistä tutkimuksista oli retrospektiivisia ja 
peräisin yhdestä keskuksesta. Teho-osastolla tapahtuvan sydämenpysähdyksen esiintyvyys 
ja siihen liittyvä kuolleisuus vaihtelivat laajalti tutkimusympäristöstä ja potilasaineistosta 
riippuen. 
Suomalaisilla teho-osastoilla jokaista 1000 tehohoitojaksoa kohti oli 29 sydämen-
pysähdystä ja sydämenpysähdyksen jälkeinen sairaalakuolleisuus oli 56%.
Sydämenpysähdystapahtumaan ja heikkoon tehohoitojaksoa edeltävään toiminta-
kykyyn liittyvät sairaalakuolleisuusriskit olivat keskenään verrannollisia. Lisäksi korkeampi 
kuolleisuusriski liittyi myös varhaiseen hoitointensiteetin nousuun erityisesti potilailla, 
joiden kuolleisuusriski oli arvioitu matalaksi sairauden vaikeusasteen perusteella 
tehohoitojakson alussa. 
Ison suomalaisen yliopistollisen sairaalan teho-osastoilla hoidetuista sydämen-
pysähdyspotilaista 58% sairaalan ulkopuolella elvytetyistä, 41% sairaalan sisällä 
elvytetyistä ja 39% teho-osastolla elvytetyistä oli elossa vuoden kohdalla primääristä 
sydämenpysähdystapahtumasta. Näistä 88-94% selvisi myös neurologisesti hyvin. 
Hoitokustannukset yhtä vuoden kohdalla elossa olevaa sydämenpysähdyspotilasta 
kohti olivat 94688 euroa ja yhtä neurologisesti hyvin selvinnyttä potilasta kohti 102722 
euroa. Hoitokustannukset olivat verrattavissa muiden tehohoidon potilasryhmien 
hoitokustannuksiin, joita pidetään yleisesti hyväksyttävinä.
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Cardiac arrest (CA), a sudden and devastating event, aff ects numerous lives annually. 
Historically, post-CA prognosis was considered grim, with only a fraction of initial CA 
victims recovering to their pre-arrest level. To improve post-CA outcomes, the concept 
of ‘chain of survival’, introduced in 1991, was widely implemented [1]. Th is concept 
encompassed the idea of an eff ective and uninterrupted initial treatment based on four 
major links: early access, early cardiopulmonary resuscitation (CPR), early defi brillation 
and early advanced treatment. Strengthening these links resulted in the improvement of 
post-CA survival regionally [2,3]. Over the past two decades, ‘chain of survival’ underwent 
only minor changes, retaining its original integrity. In the early 2000s, therapeutic 
hypothermia (TH), another crucial change in the treatment of CA, entered into clinical 
practice [4]. Whilst the role of TH remains controversial, it is possible that TH, along 
with the advanced resuscitation guidelines for special circumstances published during the 
2000s, further strengthened  the ‘chain of survival’ and its fourth link in particular, leading 
to additional improvements in post-arrest outcomes [5–8].
With an estimated 350,000 to 700,000 sudden CA events yearly in Europe alone, 
it is clear that CA poses an enormous socioeconomic burden to modern society [9,10]. 
Eventually, humanity will need to face the reality of limited resources. Th us, it is essential 
to establish a fi rm understanding of the healthcare-associated costs and cost-eff ectiveness 
regarding CA patients as well.
Originally, CA was stratifi ed according to the initial rhythm based on the rationale 
of a certain aetiology–treatment pathway. CA stratifi cation by location allows us to 
view the matter from an alternative perspective, paying more attention to patients’ peri-
arrest conditions. Whilst the features of out-of-hospital cardiac arrest (OHCA) are well-
established, in-hospital CA (IHCA) and in-ICU CA (ICU-CA) in particular have received 
less attention. A fi rm belief amongst clinicians persists, whereby outcomes following 
ICU-CA are viewed as generally very poor. In truth, given a complete physiological failure 
due to acute disease or a poor preadmission functional status, even the most eff ective and 
optimally timed CPR attempts would be of very limited value. By contrast, in-hospital 
patients, specifi cally ICU patients, are susceptible to the adverse eff ects of in-hospital 
treatments. In such cases, timely intervention to restore patients’ physiological stability 




2 REVIEW OF THE LITERATURE
2.1 Cardiac Arrest
Key Messages
• CA is an abrupt loss of spontaneous circulation potentially leading to end-organ 
damage and death.
• CA is categorised based on the initial rhythm (shockable vs non-shockable) and 
on location (out-of-hospital vs in-hospital).
• More than 3.6 million CAs occur annually worldwide, with most adult CAs 
resulting from a cardiac aetiology.
• Post-CA syndrome results from ischemia/reperfusion injury and is a key factor in 
the pathophysiology of CA-induced organ damage.
• CA treatment is complex and time-sensitive, oft en requiring an intensive care 
setting.
2.1.1 Definitions
CA is an abrupt loss of circulation due to the cessation of cardiac mechanical activity 
[11,12]. When left  untreated, CA will result in the prompt loss of consciousness, end-organ 
damage and, eventually, death. CA is not an individual disease, but rather a pre-mortal 
pathological state. Th e clinical presentation of CA varies depending on aetiology, duration 
of the circulatory failure and the presence and extent of CA-induced organ failure.
Th e return of spontaneous circulation (ROSC) is defi ned as the restoration of a 
spontaneous perfusing cardiac rhythm, leading to regaining a palpable pulse, a measurable 
blood pressure or spontaneous breathing as indicators of successful resuscitation. Time to 
ROSC marks the delay in restoring signs of circulation in the absence of on-going chest 
compressions [12].
Initial CA rhythms are stratifi ed into two groups: shockable and non-shockable. 
Shockable rhythms fall into two categories. Ventricular fi brillation (VF) represents a 
continuous desynchronised contraction of the ventricular muscle mass as a result of 
disorganised electrical activity, whilst ventricular tachycardia (VT) is a regular improper 
excitation of the ventricular muscle mass due to the abnormal conduction of an electrical 
impulse. Non-shockable rhythms include pulseless electrical activity (PEA), a state of 
electromechanical dissociation characterised by the conducted electrical impulse of the 
heart resulting in an insuffi  cient or absent heart muscle contraction. Asystole, also a non-
shockable rhythm, is defi ned as the complete absence of both an electrical impulse and 
mechanical activity of the heart [13].
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2.1.2 Classification
CA is traditionally classifi ed according to two variables: an initial cardiac rhythm (shockable 
vs non-shockable) and the location of occurrence (out-of-hospital vs in-hospital). Th e 
rationale behind the cardiac rhythm–based classifi cation lies in determining the initial 
treatment and diagnostic approach taken [14,15]. Location-based classifi cation, however, 
is based on the understanding that IHCA patients might have multiple comorbidities 
potentially infl uencing resuscitation outcomes, thereby diff ering from the majority of 
OHCA patients [16]. Yet, the availability of advanced life support is typically better and 
delays to treatment initiation are shorter for IHCA patients [17].
ICU-CA represents a subgroup of IHCA. Still, notable diff erences exist in peri-arrest 
factors amongst ICU-CA compared to the remainder of IHCA patients. Specifi cally, ICU 
patients are continuously monitored, advanced treatment resources are readily available 
and delays to initial CA treatment are virtually non-existent. However, ICU patients are 
also generally sicker and more vulnerable to treatment-associated adverse events than 
other in-hospital patients [18–20].
2.1.3 Aetiology
Cardiovascular diseases stand as the leading causes of death globally [21,22]. Approximately 
40% of all deaths under the age of 75 result from a cardiovascular pathology, with coronary 
heart disease responsible for 60% to 70% of all sudden cardiac deaths [23,24]. Furthermore, 
roughly 60% to 80% of OHCAs primarily result from a cardiac pathology, most commonly 
ischaemic heart disease, followed by other cardiovascular causes, such as structural heart 
disease and primary arrhythmias [25–28]. Non-cardiac causes, such as trauma, bleeding, 
pulmonary embolism, asphyxia and drug-overdose, are responsible for the remainder of 
OHCAs [25,29].
In addition, cardiac disease represents the most common cause of IHCAs, responsible 
for 50% to 60% of arrests. Hypoxia and pulmonary pathologies cause approximately 
15% to 20% of IHCAs, followed by less common aetiologies, such as thrombosis, cardiac 
tamponade, hypovolemia and sepsis [30–32].
2.1.4 Epidemiology
Th e estimated incidence of CA varies from between 30 and 100/100,000 person-years for 
OHCA and from 1 to 6/1000 hospital admissions annually for IHCA. Th ese fi gures can be 
extrapolated to establish estimates of 350,000 to 700,000 sudden CAs annually in Europe, 
300,000 to 500,000 CAs annually in the US, over 2.5 to 4 million CAs annually in Asia 
and 20,000 to 30,000 sudden CAs annually in Australia and New Zealand [9,10,33–38]. 
With an average of 78 OHCAs per 100,000 person-years and 2.2 IHCAs per 1000 hospital 
admissions, CA incidence in Finland is similar to that in other countries [39,40].
Yet, the incidences of VF/ VT OHCA continue to decrease, possibly due to the 
increased placement of implantable cardiac defi brillators, improved treatment and more 
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active primary prevention of coronary heart disease [41–45]. However, an increase in non-
cardiac OHCAs has also been recently noted [46].
Whilst the epidemiology of OHCA has received extensive attention, data on in-hospital 
arrest remain limited. Nearly half of all IHCAs occur in ICU settings [47–49]. Yet, ICU-CA 
has received little attention thus far, and most of the ICU-CA data are based on single-
centre studies [50].
2.1.5 Initial cardiac rhythms
Approximately 25-50% of OHCAs have VF as the initial CA rhythm on the fi rst assessment, 
although prevalence of shockable rhythms has declined over the past several decades 
[39,43,51–55]. Yet, the prevalence of initial shockable rhythms can exceed 70% if the 
rhythm is recorded soon aft er collapse [56,57].
Despite potentially shorter delays in the initiation of CPR and initial rhythm analysis, 
the reported prevalence of shockable rhythms in IHCA patients varies from 23% to 51%, 
which is quite similar to OHCA [17,47,58–60].
2.1.6 Post-cardiac arrest syndrome
CA induces global hypoperfusion, leading to generalised ischaemia; ROSC, if achieved, 
causes reperfusion. A whole-body ischaemia and subsequent reperfusion results in 
post-CA syndrome, a condition unique in its defi nable cause, time course and typical set 
of pathological processes described as early as the 1970s [61–63]. Furthermore, post-CA 
syndrome includes a combination of symptoms, such as post-CA brain injury, post-
arrest myocardial dysfunction, a systemic ischaemia–reperfusion response and persistent 
precipitating pathology.
2.1.6.1 Post-cardiac arrest brain injury
CA-related brain injury occurs within the fi rst minutes of ischaemia since the brain is the 
most ischaemia-sensitive organ. Brain injury involves numerous and complex damage 
mechanisms, including excitotoxicity, altered calcium homeostasis, the formation of free 
radicals, pathological protease cascades, activation of cell-death signalling pathways, 
microcirculatory failure and the malregulation of cerebral blood fl ow [64–68] Post-arrest 
factors that may infl uence the development of brain injury are hyperoxia, hypocapnia, 
pyrexia, hyperglycemia and seizures [69–74].
2.1.6.2 Post-cardiac arrest myocardial dysfunction
Haemodynamic instability and arrhythmias are common features of the early post-
resuscitation period. Post-CA myocardial dysfunction can be detected through appropriate 
monitoring within minutes aft er ROSC, and is characterised by the signifi cant impairment 
of the left  ventricle’s contractile function. Post-CA myocardial dysfunction manifests as a 
decrease in the ejection fraction, an elevated left  ventricle end-diastolic pressure and a low 
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cardiac output. Th e eff ect is not associated with a reduced coronary blood fl ow or on-going 
myocardial ischaemia, but rather represents a stunning phenomenon transient in nature 
and responsive to inotropic drugs [75–79].
2.1.6.3 Systemic ischaemia–reperfusion response
A whole-body ischaemia–reperfusion injury resulting from CA induces a sepsis-like 
syndrome through the activation of immunologic and coagulation pathways, resulting 
in the high risk for multiple organ failure [80]. Endothelial injury, endotoxin release 
and various cytokines precipitate an early post-arrest pro-infl ammatory process and the 
activation of coagulation pathways [81,82]. Th e stress of post-arrest ischaemia–reperfusion 
signifi cantly impacts adrenal function, potentially contributing to the development of 
refractory shock [83].
2.1.6.4 Persistent precipitating pathology
Th e clinical course of the post-CA period is oft en complicated by a pre-existing acute 
pathology, such as acute coronary disease, thromboembolic condition, sepsis or trauma. 
Yet, other conditions should be readily considered whenever based on the patient history 
and clinical presentation. Various pre-existing conditions may require a specifi c treatment 
approach coordinated with post-CA organ support [84].
2.1.7 Post-arrest treatment
Treating post-CA patients remains complex and time-sensitive, occurring both in- and 
out-of-hospital and involving multiple healthcare teams at diff erent stages. Irrespective of 
the cause of CA, hypoxemia, ischaemia and reperfusion may evolve into multiple organ 
failure. Whilst the severity of post-CA syndrome varies across patients, eff ective post-CA 
treatment should consist of reversing the pathophysiological processes of the syndrome 
and identifying and treating the initial precipitating pathology. Due to the complexity of 
post-CA treatment, initial management of CA patients typically takes place in the intensive 
care setting. Th e latter involves general ICU monitoring, oft en with either protocol-based 
or on-demand advanced haemodynamic and neurological monitoring [84,85].
2.1.7.1 Intensive care
ICU is a specialised environment in the hospital setting that provides optimal and adequate 
care of patients with severe and life-threatening illnesses and injuries. Intensive care patients 
receive close and extensive monitoring of basic bodily functions and are under constant 
observation by highly trained ICU nurses. In addition, ICUs feature a higher nurse-to-
patient ratio compared to other hospital wards. Moreover, ICUs possess advanced medical 
equipment suffi  cient to support critically ill patients’ organ systems, such as mechanical 
ventilation, renal replacement therapy and advanced monitoring devices. Some specialised 
ICUs also utilise extracorporeal life support devices and equipment to support patients 
with acute hepatic failure [86].
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2.1.7.2 Specifi c treatment
Depending on the severity of the post-CA syndrome, the extent of organ damage and the 
nature of the precipitating condition, individual patients will require diff erent degrees 
of specialised care and treatment procedures. Post-CA treatment oft en requires acute 
cardiovascular interventions and haemodynamic support [87,88], targeted temperature 
management and active avoidance of hyperthermia [89–91], neurological care [92], glucose 
control [93,94] and mechanical ventilation to ensure adequate carbon dioxide removal and 
oxygenation [95–98].
2.2 Outcomes Following Cardiac Arrest
Key Messages
• Post-CA survival varies from 3% to 80% depending upon patient population and 
local settings.
• Post-CA neurological recovery continues for months and most hospital survivors 
achieve a favourable neurological outcome.
• Th e early prognosis of post-CA outcomes must be multimodal and based on an 
accurate clinical examination and additional diagnostic tools.
• Outcome prediction scores are generally of limited value in post-CA 
prognostication.
Since the rediscovery of modern cardiopulmonary resuscitation in the 1950s, numerous 
studies sought to predict outcomes aft er resuscitation. Older publications regarding both 
OHCA and IHCA patients suff ered from the universal problem of inconsistent reporting 
[99–102]. A uniform standard for reporting research on OHCA emerged in 1991, followed 
by two revisions in 2004 and 2014 [11,12,103]. Similarly, the Utstein-style reporting standard 
for IHCA studies appeared in 1997 [16]. Both recommendations provide a strong basis for 
CA research, allowing for the systematic comparison of CA-related studies. According to 
the Utstein guidelines, survival to hospital discharge or survival to 30 days should stand as 
the minimum measurement of the outcome reported and, preferably, should include data 
on six-month and one-year outcomes. In addition, evaluation of the neurological outcome 
of hospital survivors should include an estimate using a simple validated neurological score, 
such as the Cerebral Performance Category (CPC), the Overall Performance Category 
(OPC) or a modifi ed Rankin Scale, as well as ideally, an estimate of the post-CA quality of 
life [103–105].
2.2.1 Survival after OHCA
According to studies published following the emergence of the OHCA Utstein guidelines, 
survival to hospital discharge for OHCA patients varies between 3% and 10%; yet, some 
regions have achieved hospital survival of 20% to 40% [9,10,33,39,41,54,106–108]. Survival 
to hospital discharge for ICU-treated OHCAs approaches 50% [6,109]. In addition, one-
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year survival for all-rhythm OHCAs lies between 3% and 22% [110–113]. However, survival 
for OHCAs with shockable rhythms is signifi cantly better, with 20% to 60% of patients alive 
at hospital discharge [39,54,107,109] and at least 30% of patients alive at one year aft er CA 
[39,112].
2.2.2 Survival after IHCA
Approximately 6% to 22% of IHCA patients survive to hospital discharge 
[47,48,50,59,114,115]. One-year survival varies between 5% and 29% [102,114]. Similar to 
OHCAs, hospital survival following IHCA is better for patients with shockable rhythms, 
reaching 20% to 42% [47,58–60,116]. IHCA patients also exhibit higher survival rates if 
CA occurs on a weekday (hospital survival 17% vs 20%) and during the daytime (hospital 
survival 15% vs 20%) [117].
2.2.3 Survival after ICU-CA
Depending on the study population, hospital survival aft er ICU-CA varies from 0% to 
79% [18,118]. For instance, two major multicentre studies reported hospital survival aft er 
ICU-CA of 16% [50,119]. Yet, 70% of post-cardiac surgery ICU-CA patients were alive at 
one year, although mortality in the mixed-ICU population was signifi cantly higher, with 
only 2% surviving to one year aft er ICU-CA [118,120,121].
2.2.4 Neurological and functional outcomes
Most studies report neurological outcomes such as CPC or OPC in accordance with the 
Utstein guidelines [12,16]. Both evaluation systems are directly comparable and defi ne a 
favourable outcome as CPC/OPC scores of 1 to 2 and unfavourable outcomes as CPC/OPC 
scores of 3 to 5 (see Table 1) [11,34].
Amongst hospital survivors, a good neurological outcome is achieved in 70% to 93% 
of OHCAs, 50% to 86% of IHCAs and 77% to 83% of ICU-CAs [48,50,60,109,111,117,122–
125]. Although CPC represents the most widely used tool to evaluate neurological outcomes 
following CA, some concern exists regarding overestimating favourable neurological 
survival, whereby a signifi cant number of patients with CPC 1 to 2 exhibit a marked 
cognitive dysfunction [126–129]. Th e timing of the optimal evaluation of neurological 
and functional outcome remains unclear. However, some evidence suggests that recovery 
continues for at least months aft er the initial arrest, thus indicating the need for repeated 
evaluation during the recovery process [130,131]. Table 2 summarises the published 
incidence and outcome estimates for CA patients based on CA location.
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Table 1. Outcome of Brain Injury: Th e Glasgow-Pittsburgh Cerebral Performance and Overall 
Performance Categories
Cerebral Performance Categories Overall Performance Categories
1. Good cerebral performance. Conscious. Alert, 
able to work and lead a normal life. May have 
minor psychological or neurological defi cits (mild 
dysphasia, nonincapacitating hemiparesis, or 
minor cranial nerve abnormalities)
1. Good overall performance. Heathy, alert, 
capable of normal life. Good cerebral 
performance (CPC1) plus or only mild 
functional disability from noncerebral 
organ system abnormalities.
2. Moderate cerebral disability. Conscious. Suffi  cient 
cerebral function for part-time work in sheltered 
environment or independent activities of daily life 
(dressing, travelling by public transportation, and 
preparing food). May have hemiplegia, seizures, 
ataxia, dysarthria, dysphasia or permanent memo-
ry or mental changes.
2. Moderate overall disability. Conscious. 
Moderate cerebral disability alone (CPC 
2) or moderate disability from noncere-
bral system dysfunction alone or both. 
Performs independent activities of daily 
life (dressing, travelling, and food prepa-
ration). May be able to work part-time in 
sheltered environment but disabled for 
competitive work.
3. Severe cerebral disability. Conscious. Dependent 
on others for daily support because of impaired 
brain function (in an institution or at home with 
exceptional family eff ort). At least limited cog-
nition. Includes a wide range of cerebral abnor-
malities from ambulatory with severe memory 
disturbance or dementia precluding independent 
existence to paralytic and able to communicate 
only with eyes, as in the locked-in syndrome. 
3. Several overall disability. Conscious. 
Severe cerebral disability alone (CPC 
3) or severe disability from noncerebral 
organ system dysfunction alone or both. 
Dependent on others for daily support.
4. Coma, vegetative state. Not conscious. Unaware of 4. Same as CPC 4.
surroundings, no cognition. No verbal or psycho-
logical interactions with environment.
5. Death. Certifi ed brain dead or dead by traditional 
criteria. 
5. Same as CPC 5.
CPC, Cerebral Performance Categories.
Table is adopted from Cummins et al. Circulation, vol. 84, 1991, pp. 960–75 with permission from Wolters 
Kluwer Health










(20–42% for VF/VT) 0–79%
One-year 
survival 3–22% 5–29% 2–70%
Neurological outcome at 
hospital discharge 70–93% CPC 1–2 50–86% CPC 1–2 77–83% CPC 1–2
OHCA, out-of-hospital cardiac arrest; IHCA, in-hospital cardiac arrest; ICU, intensive care unit; ICU-




2.2.5 Prediction of outcome
Most deaths during the fi rst three days following CA occur due to acute cardiovascular 
failure [132,133]. Amongst patients surviving to ICU admission, 60% of OHCAs and 
approximately 25% of IHCAs die during the same hospital stay as a result of post-CA brain 
injury [132–135]. Th e most common cause of death in patients with an anticipated poor 
outcome is the withdrawal of life-sustaining therapy [133,136]. Th is practice renders the 
existence of reliable prediction tools and established prognostic protocols essential.
Several studies have proposed factors possibly aff ecting survival. Some of these factors 
carry a clear relationship with post-CA outcomes, whilst the eff ect others remains more 
vague.
2.2.5.1 Pre-arrest factors
Several studies identifi ed pre-arrest factors associated with outcomes following CA. Th ese 
include an advanced age, poor cardiac health and diabetes, metastatic cancer, sepsis, renal 
failure, stroke and a homebound lifestyle [137–141]. Additionally, the socioeconomic 
environment may associate with post-CA survival. For instance, a low socioeconomic 
status signifi cantly decreased the chance of receiving CPR in the case of an arrest according 
to two studies from Asia and the US, although it is unclear whether these fi ndings can be 
extrapolated to other geographic areas [142,143]. 
2.2.5.2 Intra-arrest factors
Both a prolonged interval from collapse to the initiation of CPR and a prolonged time 
to ROSC carry an undisputed association with a poor outcome. Other factors associated 
with poor outcomes following CA include poor adherence to CPR guidelines, a low intra-
arrest end-tidal carbon dioxide level, long preshock pauses and extensive interruptions 
in assessing the rhythm or providing ventilation, as well as an initial cardiac rhythm of 
asystole [84].
2.2.5.3 Clinical predictors
Neither pre- nor intra-arrest factors’ association with poor outcome is strong enough 
to serve as an independent prediction tool. Th us, resuscitation guidelines advocate 
for the practice of multimodal prognostication that includes clinical examination, 
electrophysiological investigation, diagnostic imaging and biomarkers. [85,135].
Clinical signs associated with poor outcomes include the bilateral absence of a 
pupillary light refl ex 72 h aft er ROSC, a bilaterally absent corneal refl ex and an absent or 
extensor motor response 72 h aft er ROSC [144,145]. Both the corneal refl ex and motor 
response can be suppressed by sedatives and neuromuscular blockers; thus, suspicion of 
residual sedation and paralysis mandates prolonging the observation period. Myoclonus is 
another clinical entity with a well-established association with poor outcome. A myoclonic 
status within 48 h of ROSC strongly predicts an unfavourable neurological outcome, yet 
there are several case reports of good neurological outcome despite that association. [146]
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Whilst clinical examination is inexpensive and easy to conduct, the results are also 
readily visible to treatment teams, thus possibly infl uencing clinical decisions and ultimately 
resulting in a ‘self-fulfi lling prophecy’ [135]. Electrophysiological investigations, specifi cally 
short-latency somatosensory-evoked potentials (SSEPs) and electroencephalography 
(EEG), have proved useful as prediction tools in post-arrest comatose patients. For 
instance, the bilateral absence of N20 SSEP waves predicts a poor outcome with a high 
positive predictive value [147]. Furthermore, the absence of an EEG reactivity predicts a 
poor outcome, although the lack of standardisation and a modest inter-rater agreement 
pose considerable limitations to its clinical application. In patients treated with therapeutic 
hypothermia (TH), the presence of an EEG-confi rmed status epilepticus during TH or 
aft er rewarming, as well as a late persistent burst-suppression pattern, oft en precede a poor 
outcome [148,149]. In addition, cerebral oedema and a reduced grey-to-white matter ratio 
on a head CT scan predict a poor outcome [150]. Magnetic resonance imaging (MRI) can 
improve the predictive value due to its high sensitivity in identifying an ischaemic brain 
injury. Furthermore, MRI can help identify extensive anoxic changes despite normal results 
using other predictors [151]. A series of serum biomarkers have been evaluated as predictors 
of a poor outcome aft er CA. Neuron-specifi c enolase (NSE) carries the most extensive 
scientifi c basis for its use as a predictor, although it is highly infl uenced by haemolysis and 
neuroendocrine tumours [152]. Some evidence suggests that the discriminative value of 
NSE improves at 48 and 72 h following arrest and any increase in NSE levels between two 
time points may carry an additional predictive value [153].
2.2.5.4 Outcome prediction scores
Diff erent severity-of-illness scores are used widely in the prediction of outcomes for ICU 
patients. [154,155] Th e most commonly used scores are the Acute Physiology and Chronic 
Health Evaluation score (APACHE) with its three revisions[156–159] and Simplifi ed Acute 
Physiology Score (SAPS) with its two revisions. [160–163] Both APACHE and SAPS predict 
the risk of mortality based on data from the fi rst day of ICU stay. In addition, there is a 
number of repetitive severity-of-illness scores that rely on data collected daily, either for the 
fi rst three days or throughout an ICU stay [154]. Th e most notable repetitive scores are the 
Sequential Organ Failure Assessment (SOFA) score and the Multiple Organ Dysfunction 
Score (MODS) [164,165].
Notably, APACHE II and APACHE III scores had only  modest prediction 
performance for mortality and neurological outcome in both OHCA and IHCA. [166–
168]. With moderate discrimination abilities, neither SAPS II nor SAPS 3 performed better 
than specifi c intra-arrest predictors and should not be used as prediction tools for post-CA 
outcomes [169,170]. Several studies found that cardiovascular and renal components of the 
SOFA score associated with the outcome aft er CA; however, the usefulness of the SOFA 
score as an outcome predictor in CA patients remains unclear [171,172]. No systematic 
evaluation of MODS as an outcome predictor aft er CA has been performed so far.
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All of the abovementioned severity-of-illness models were developed for a general 
ICU population. Th us, they lack CA-specifi c data, such as time delays, initiation of 
bystander CPR and the initial cardiac rhythm. Furthermore, several CA-specifi c scores 
were developed for early post-CA outcome prediction. For instance, the OHCA score was 
developed to predict neurological functioning aft er successful resuscitation in unselected 
OHCA patients upon hospital admission. Th is score includes the initial cardiac rhythm, 
the ‘no-fl ow’ and ‘low-fl ow’ time intervals as well as the serum creatinine and lactate 
measurements. Th e OHCA score initially showed good discriminative abilities on both the 
development [area under the receiver operating characteristic curve (AUC) = 0.82] and 
validation cohort (AUC = 0.88), and a good calibration [173]. Despite these fi ndings, the 
specifi city of the OHCA score remained low and the performance of the model could not be 
reproduced in later studies, suggesting a poor predictive power for the score [167,173–175]. 
Th e Cardiac Arrest Hospital Prognosis (CAHP) score was developed in France, and is based 
on the Sudden Death Expertise Centre registry for the early prediction of unfavourable 
neurological outcomes, defi ned as a CPC score of 3, 4 or 5 in OHCA patients at hospital 
discharge [176]. Th e CAHP score implements nomogram with seven independent 
predictors: age, a non-shockable rhythm, time from collapse to basic life support, time 
from the initiation of basic life support to ROSC, home-setting arrest, epinephrine dose 
and arterial pH. Th e score demonstrated excellent discriminative abilities (AUC = 0.93) in 
the development cohort and a good to excellent discrimination in two external validation 
cohorts (AUC = 0.85 and 0.91, respectively). However, according to the authors, the CAHP 
score has not been validated beyond the French healthcare system [176]. More recently, 
the Targeted Temperature Management (TTM) score emerged [177]. Th is score is intended 
for the early prediction of survival and neurological outcomes at six months in comatose 
OHCA patients with a presumed cardiac cause of arrest and was developed from the TTM 
trial cohort. Th e TTM score includes ten independent predictors: age, home-setting arrest, 
a non-shockable rhythm, duration of the no-fl ow and low-fl ow periods, administration of 
epinephrine, the bilateral absence of corneal and pupillary refl exes, a Glasgow Coma Score 
motor response of 1, arterial pH and the carbon dioxide level. Th e TTM score demonstrated 
a good discriminative performance in the validation cohort (AUC = 0.84). However, the 
authors did not perform an external validation of the TTM score. Notably, both the OHCA 
and CAHP scores showed only a fair discrimination in the same TTM trial–based cohort 
[177].  None of these three specifi c CA prediction scores is applicable to IHCA patients. 
Since multiple post-arrest factors infl uence the outcome of CA, the clinical utility of 
outcome predictions on admission remains questionable, rendering the abovementioned 
scores invalid for clinical decision-making for individual patients.
An alternative to severity-of-illness scores are activity-based scores. One of the most 
extensively used activity-based scores is the Th erapeutic Intervention Scoring System 
(TISS). TISS, originally introduced in 1974, was suggested by its authors as an indicator 
of patients’ clinical condition [178]. Th e original TISS-76 underwent revision in 1981 and 
eventually, aft er modernisation, evolved into TISS-28 [179,180],  the latter serving as the 
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basis for the Nursing Manpower Use Score (NEMS) [181]. Although originally suggested as 
a severity-of-illness index, TISS and its variations currently serve as widely accepted tools 
to measure nursing workload and consistent means of describing ICU costs [181,182].
2.3 Healthcare-Associated Costs and Cardiac Arrest
Key Messages
• Caring for critically ill patients remains expensive.
• Cost-eff ectiveness and cost-utility represent the preferred measures for estimating 
costs in critical care settings.
• Health economic analyses ideally should include estimates of both direct and 
indirect costs.
• A frequently cited incremental cost-eff ectiveness ratio of US$50,000 per quality-
adjusted life-year (QALY) likely underestimates societal willingness to pay for 
health benefi ts.
• Data on CA-related healthcare costs remain limited to several single-centre studies.
• Public access defi brillation and therapeutic hypothermia are considered as cost-
eff ective interventions. 
Critical care is generally considered an expensive and resource-demanding specialty [183]. 
In 2010, critical care medicine costs in the US reached over US$4000 per in-patient day, or 
a total of US$108 billion per year, accounting for 13% of all hospital costs, 4% of national 
healthcare expenditures and 0.7% of the US gross domestic product (GDP). [184] From 
2000 to 2010, the costs of critical care medicine nearly doubled, with further increases 
expected [184]. 
2.3.1 Assessment of costs in critical care
Four major types of cost analyses have been used to assess the economic impact of medical 
interventions in healthcare settings. Th ese consist of cost-minimisation, cost-benefi t, cost-
eff ectiveness and cost-utility analyses.
2.3.1.1 Cost-minimisation
In cost-minimisation analysis, medical interventions with comparable indications and 
outcomes are evaluated in order to identify the least expensive option. Th e analysis requires 
the preselection of interventions with clinically equivalent outcomes [185]. Th is type 
of analysis is relatively easy to perform; however, it is not recommended for critical care 
settings due to the complexity of critical care patients and its inability to assess relationships 
across tested interventions related to outcomes and risks [186].  
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2.3.1.2 Cost-benefi t
A cost-benefi t analysis compares the costs and benefi ts of diff erent interventions by 
assigning a monetary value to measure an eff ect. Both benefi ts and costs are expressed 
in monetary terms and include a time-value adjustment. Th e analysis has three general 
approaches: the human capital approach, which involves measuring costs assumed to 
be related to outcomes; the revealed preferences approach, which relies on observing an 
individual’s behaviour as an estimate of a benefi t; and the contingent valuation approach, 
which uses the reported willingness to pay as a measure of assumed benefi ts [185,187].
2.3.1.3 Cost-eff ectiveness
A cost-eff ectiveness analysis evaluates the costs of resources spent on a specifi c intervention 
in order to achieve an intended outcome. Contrary to the cost-benefi t analysis, outcomes are 
measured on a one-dimensional score, such as life-years gained, number of deaths avoided 
and number of ICU admissions. Th is type of analysis does not require the assignment of 
monetary values to outcomes and takes into account diff erent types of costs.  Th e primary 
limitations of the cost-eff ectiveness analysis include the need for sensitivity analyses or 
incremental cost-eff ectiveness ratios in order to avoid misinterpretations when comparing 
outcomes for alternative treatment options [185,187]. A specifi c type cost-eff ectiveness 
measure is the eff ective cost per survivor (ECPS), measured as the total cost for survivors 
and non-survivors within a specifi c group divided by the number of survivors within the 
same group [188].
2.3.1.4 Cost-utility
A cost-utility analysis, similar to a cost-eff ectiveness analysis, also estimates the ratio 
between the costs of an intervention and the benefi t produced. However, the benefi t of the 
intervention is measured in terms of the number of years lived in full functional health. 
Th e most common measure of outcomes in cost-utility analyses is the quality-adjusted life-
year (QALY), a metric that corresponds to one year lived in a hypothetical state of ‘perfect 
health’. Th is type of analysis represents the preferred method in the estimation of ICU-
related costs due to its more patient-centred approach and its ability to compare outcomes 
across diff erent types of interventions [185,189].  
2.3.2 Types of costs
Health economists distinguish between two major types of costs. Direct costs include 
the costs of all resources (that is, treatment and diagnostic procedures, medications and 
personnel work hours) consumed in order to achieve the desired clinical outcomes. By 
contrast, indirect costs refer to the loss of resources due to lost productivity or the need for 
additional payments (that is, sick leave, disability pension and the loss of national taxes) 
resulting from specifi c clinical outcomes [188]. Whilst direct costs are typically extensively 
reported, quantifi cation of indirect costs remains a much more complex task oft en requiring 
robust approximations. 
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2.3.3 Acceptable costs for healthcare interventions
Th e most frequently cited incremental cost-eff ectiveness threshold for the justifi cation of 
a medical intervention is US$50,000 in the US [190]. Th e corresponding thresholds vary 
from £20,000 to £30,000 in the UK and €80,000 in the Netherlands [183,191,192]. However, 
some researchers believe that these monetary thresholds do not correlate with society’s 
willingness to pay and are, in fact, too low [193–195]. More recent estimates suggest 
applying values between US$100,000 and US$300,000 per QALY with the simultaneous use 
of several thresholds instead of a single value being more appropriate [193,194]. 
2.3.4 Cardiac arrest-related costs
Th e exact CA-related consumption of resources and expenses remains unknown and, thus 
far, only a limited number of publications have addressed the matter. Due to diff erences 
in methodology and the lack of uniform reporting guidelines, estimated costs are highly 
variable. Most publications evaluate treatment-associated costs for OHCAs [196–200]. 
Th us, only a few studies report treatment-associated costs for IHCAs, either as a separate 
patient population or clustered with OHCAs [201,202]. Furthermore, most studies report 
either hospital costs or hospital and pre-hospital costs, with only one study reporting 
post-hospital costs [199]. Yet, one recent study on CA-related healthcare costs reported 
a steady increase in CA treatment–related expenses [203]. Whilst data on the overall 
cost-eff ectiveness of CA treatment remain lacking, the implementation of public access 
defi brillation and TH in witnessed VF OHCAs are considered cost-eff ective interventions 
[204,205]. 
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3 PURPOSE OF THE STUDY
Th is study aimed to investigate the outcomes and healthcare-associated costs of CA patients 
treated in Finnish ICUs, focusing specifi cally on the following objectives:
1) To systematically review earlier studies on ICU-CA, to determine the incidence 
and hospital mortality of ICU-CA in Finnish ICUs and to investigate outcomes 
and healthcare-associated costs in ICU-treated CA patients. (studies I, II and IV)
2) To study the association of early treatment intensity and specifi c therapeutic 
interventions and the administration of CPR related to hospital mortality in 
Finnish ICU patients (study III).
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4 SUBJECTS AND METHODS
4.1 Study Se   ng and Popula  on
Study I consists of a systematic review of the literature. Studies II through IV are based on 
the Finnish Intensive Care Consortium (FICC) database and include ICU patients from 
all participating FICC hospitals from 2003 through 2013 (II, III) and from a single tertiary 
teaching hospital from 2005 through 2013 (IV). Table 3 summarises the key characteristics 
of the studies.
Table 3. Basic characteristics of the studies
Study I Study II Study III Study IV







Data source PubMed, CINAHL, 
Cochrane Database
FICC FICC Multiple databases 
(FICC, SII, MH, 
FPRC)
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intensity on hospital 





healthcare costs of 
ICU-treated CA 
patients
FICC, Finnish Intensive Care Consortium; SII, the Social Insurance Institution of Finland; MH, Meilahti 
Hospital; FPRC, Finnish Population Register Centre, CINAHL, Cumulative Index to Nursing and Allied 
Health Literature; CA, cardiac arrest; ICU, intensive care unit, ICU-CA, in-ICU cardiac arrest.
4.1.1 Finnish Intensive Care Consortium (II, III, IV)
FICC, a cooperative benchmark project established in 1994, aims to improve the quality of 
intensive care in Finland. FICC comprises 22 acute care hospitals’ ICUs covering mainland 
Finland and over 90% of the Finnish population. Th e FICC database prospectively collects 
demographic, treatment-specifi c and severity-of-illness data. Physiological data are 
obtained directly from ICU clinical information systems that collect data automatically 
from patient monitors, ventilators and laboratory systems. ICU staff  manually enter 
information on comorbidities, the type of admission, diagnoses and vital status at ICU and 
hospital discharge. Subsequently, collected data undergo a multilevel validation process 
that includes the automatic fi ltering of technical artefacts and manual validation by local, 
specially trained personnel [6,206].
For substudies II through IV, the FICC database provided data on preadmission 




Oncology Group (WHO/ECOG) classifi cation implemented by FICC (see Table 4) [207], 
admission diagnoses, common activity and severity-of-illness scores and components, as 
well as data on hospital mortality, age, gender and length of ICU and hospital stays.
Table 4. Modifi ed ECOG performance status implemented by FICC
Grade Performance status
0 Able to carry out work or equal (retired).
1 Ambulatory and capable of all self-care, but unable to carry out any work activities.
2 Partially dependent. Needs help in self-care.
3 Fully dependent. Cannot carry on any self-care. 
ECOG, Eastern Cooperative Oncology Group; FICC, Finnish Intensive Care Consortium. Table adopted 
from Oken MM, Am J Clin Oncol 1982;5:649–55 with permission from Wolters Kluwer Health
4.1.2 Finnish healthcare and social security system (IV)
Finland has a predominantly public healthcare system funded by the government, 
municipalities and private or government-subsidised insurance companies. Th e Social 
Insurance Institution of Finland (SII) is a government agency that administers all social 
security funds in Finland. Th e Finnish Population Register Centre is a government agency 
that provides demographic information to Finnish residents, public administrations, 
businesses and communities. Th e database of the Finnish Population Registry Centre 
collects data on every birth or death event for each Finnish resident. Every Finnish citizen 
and every person residing in Finland permanently has a unique personal identifi cation 
number. Every. Furthermore, every Finnish resident is also entitled to full social security.
Th e Finnish mainland is divided into 20 hospital districts. Each district has its own 
major hospital, identifi ed as the central hospital. Th ere are 15 non-university central 
hospitals; each hospital has one adult ICU that, in many cases, also treats children 
older than infant-age. Five university hospitals have major ICUs with a mixed profi le of 
patients. However, Helsinki University Hospital also has four specialised ICUs–specifi cally, 
neurosurgical, trauma, cardiosurgical and paediatric–which were not members of FICC 
during the study period.
4.1.2.1 Meilahti Hospital (IV)
Meilahti Hospital is the largest of the Helsinki University Hospitals. Meilahti Hospital 
functions as the primary referral centre for all CA patients in the greater Helsinki area 
and the Hospital District of Helsinki and Uusimaa, with a combined population of 
approximately 1.6 million. At the beginning of the study period, Meilahti Hospital had four 
ICUs: surgical ICU, general mixed ICU, cardiosurgical ICU and medical ICU. Subsequently, 
the surgical and mixed ICUs were combined into a single unit. All ICUs except for the 
cardiosurgical ICU were members of FICC during the entire study period.
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4.1.3 Definition of cardiac arrest (II, IV)
Th e FICC database does not collect CA-specifi c data. Th us, CA patients were identifi ed as 
follows. Patients with an admission diagnosis of CA according to APACHE III admitted to 
ICUs from hospital emergency departments represented the OHCA group; patients with an 
APACHE III admission diagnosis of CA admitted to ICUs from general wards, diagnostic 
or procedural units, operating room or post-anaesthesia care units were classifi ed as the 
non-ICU IHCA group; and fi nally, patients with a positive value of TISS-76 ‘cardiac arrest 
and/or countershock within 48 h’ and an APACHE III admission diagnosis other than CA 
formed the ICU-CA group.
4.1.4  Intensive care unit cardiac arrest in Finnish ICUs (II)
Th is substudy included all adult (≥18 years) ICU admissions from the FICC database 
treated between 2003 and 2013. Patients with an admission diagnosis of CA according 
to APACHE III were excluded from the analyses as out-of-ICU CAs. Here, ICU-CA was 
defi ned according to the above-mentioned criteria. All other admissions were counted as 
non-CAs. Mortality analyses included only the initial ICU admission and only the fi rst CA 
event for patients with multiple ICU stays and/or multiple CAs during the same hospital 
stay. APACHE III admission diagnosis-based subgroup analyses were performed for post-
cardiac surgery and neurosurgical or neurological admissions.
4.1.5 Healthcare-associated costs and outcomes after ICU-treated 
cardiac arrest (IV)
Th is substudy’s population included all OHCA, IHCA and ICU-CA patients treated at 
Meilahti Hospital ICUs between 2005 and 2013. CA patients were initially identifi ed from 
the FICC database according to the abovementioned CA defi nition, and were cross-checked 
with Meilahti Hospital’s electronic health records (EHRs). Only the initial ICU admission 
and the fi rst CA event were included in this substudy.
4.1.6 Treatment intensity and mortality amongst ICU patients (III)
Th is substudy included all adult ICU patients with a length of ICU stay ≥ 3 days from 
all participating FICC hospitals between 2003 and 2013. All patients with missing data 
were excluded. For the purpose of mortality analyses only the fi rst ICU admission was 
considered.
4.2 Data Collec  on
4.2.1 Systematic literature review (I)
A systematic search of previous research (published from 1 January 1990 through 31 
December 2012) on ICU-CA was performed in January 2013 using PubMed, CINAHL and 
the Cochrane Database of Systematic Reviews. Th e search included the following medical 
Subjects and methods
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subheadings (MeSHs): ‘heart arrest’ AND ‘intensive care unit’ OR ‘critical care’ OR ‘critical 
care nursing’ OR ‘monitored bed’ OR ‘monitored ward’ OR ‘monitored patient’. Following 
the initial database search, the articles were screened based on the title and/or abstract and 
checked for the inclusion and exclusion criteria (see Table 5) and duplicates according to 
the PRISMA guidelines [208]. Only studies published in English language were included. 
Quantitative analyses were deliberately omitted due to the marked heterogeneity of the 
reviewed studies’ populations.
Table 5. Inclusion and exclusion criteria applied to the ICU-CA publications (study I)
Inclusion criteria
Studies focused on ICU-CA
Adult patients
ICU-CA incidence and/or outcome data reported
Exclusion criteria
Studies focused on out-of-ICU CA only
Paediatric patients
Duplicate publications
ICU, intensive care unit; CA, cardiac arrest; ICU-CA, in-ICU cardiac arrest.
Aft er the initial search and screening process, publications focused on incidence and 
outcomes of in-ICU cardiac arrest in adults were accepted for detailed review. A customised 
quality assessment score was developed to evaluate the methodological quality of the 
selected articles. Th e quality assessment scoring included the type of study, characteristics 
of the study setting and population, as well as specifi c CA data such as the defi nition of CA, 
time to ROSC, initial cardiac rhythm, post-CA outcomes and data on special resuscitation 
techniques (Table 6). Th e maximum quality assessment score of 22 indicated an excellent 
methodological quality of the study, whilst the minimum score of 0 corresponded to a poor 
quality study. Th e defi nition of CA and estimation of incidence and survival rates were in 
accordance with the in-hospital Utstein guidelines [16]. Post-CA survival included the 
initial survival defi ned as survival ≥24 h, survival to ICU discharge, survival to hospital 
discharge and long-term survival defi ned as survival for six months or longer. A good 
neurological outcome was defi ned as a CPC score of 1 and 2 or the ability of the survivor 
to complete everyday activities either independently or with minimal help [11,104]. Two 
authors evaluated the selected articles’ methodological quality according to the customised 
quality assessment score. Agreement between the reviewers’ assessments was measured 
using a weighted kappa score. Any disagreement between two initial reviewers was resolved 
through discussion aft er an additional independent review by a third author.
Subjects and methods
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Table 6. Evaluation criteria for methodological quality of the studies included in the systematic 
review of the literature (I)
Evaluation criteria points max. 22
1. Study type
    Focused prospective study (4 points)
    Prospective resuscitation registry (3 points)
    Prospective ICU registry (2 points)
    Retrospective (1 point)
 4
2. ICU defi nition/staffi  ng reported 1
3. General ICU/patient profi le outlined 1
4. Cardiac arrest incidence: cardiac arrest/ICU admission 2
5. Cardiac arrest clearly defi ned 1
6. Initial arrest rhythm reported 1
7. Cardiac arrest aetiology reported 1
8. Initial ICU admission diagnosis 1
9. Time intervals (1 point each)
    Time to initiation of CPR 
    Time to ROSC
2
10. Reporting of clinical factors found to correlate with the occurrence of CA (e.g. 
changes in physiological parameters, acute illness scoring systems, etc.)
1
11. Outcome data (1 point each)
     24h survival
     ICU discharge
     Hospital discharge
     Long-term survival (minimum 180 days)
4
12. Neurological outcome (1 point) or quality of life (1 point) aft er hospital discharge 2
13. Data on special resuscitation techniques and unconventional treatment strategies 
(e.g. open-chest CPR)
1
ICU, intensive care unit; CPR, cardiopulmonary resuscitation; ROSC, return of spontaneous circulation. 
Table reprinted from Efendijev I, Resuscitation 2014;85:472–9 with permission from Elsevier
4.2.2 Intensive care unit cardiac arrest in Finnish ICUs (II)
All required data for the substudy were obtained from the FICC database. Primary 
outcomes consisted of the incidence of ICU-CA calculated as the ratio of ICU-CA events 
to the total number of ICU admissions, whilst hospital mortality was calculated as the 
percentage of ICU-CA non-survivors taken from the total number of ICU-CA events.
4.2.3 Healthcare-associated costs and outcomes in ICU-treated cardiac 
arrest patients (IV)
Initially, CA patients treated in Meilahti Hospital’s ICUs were identifi ed through the 
FICC database. Subsequently, based on the personal identifi cation numbers, patients 




Insurance Institution of Finland. In addition to the data provided by FICC, CA-specifi c 
data were obtained from Meilahti Hospital’s EHRs. Th ese data included the specifi c CA 
location, the initial cardiac rhythm, time to ROSC and the neurological outcome at one year 
aft er CA according to CPC. Total healthcare-associated costs consisted of the hospital costs, 
rehabilitation costs and social security costs. Hospital costs were calculated as the costs for 
the entire treatment period, including costs of personnel, surgery, diagnostic procedures, 
the ICU stay and the general ward stay. Hospital costs were obtained directly from Meilahti 
Hospital’s billing records. In addition, rehabilitation costs were calculated by multiplying 
the length of the stay on the rehabilitation unit by the daily cost on the designated care 
unit based on a report from the Finnish National Institute for Health and Welfare [209]. 
Th e Social Insurance Institution of Finland database provided data on the social security 
costs, which consisted of disability allowances, sickness allowances, private physician and 
physiotherapist costs, prescription drug costs and medical transport expenses.
4.2.4 Treatment intensity and mortality amongst ICU patients (III)
Th e data required for this substudy were obtained from the FICC database. Early treatment 
intensity was described as the sum of the daily TISS-76 points for the fi rst three ICU days. 
Changes in the early treatment intensity were calculated as the diff erence in the daily TISS-
76 score between day three and day one (ΔTISS). Signifi cant therapeutic interventions 
were defi ned as TISS items of 3 and 4 points. Standard interventions, such as ‘arterial line 
placement’ and ‘intravenous boluses’, were excluded, as well as TISS items characteristic of 
the specifi c patient population (Tables 7a and 7b).
Table 7a. TISS 4-point items included in study III
TISS 4-point items Prevalence in the study 
population (%)
Cardiac arrest and/or countershock within 48 h 9
Controlled ventilation with or without PEEP 47
Controlled ventilation with intermittent or continuous muscle relaxants 24
Pulmonary artery catheter 31
Atrial or ventricular pacing 6
Haemodialysis in unstable patient 14
Induced hypothermia 5
Pressure-activated blood infusion 3
Platelet transfusion 14
Emergency operative procedures (within past 24 h) 29
Emergency endoscopy or bronchoscopy 19
Vasoactive drug infusion (>1 drug) 41
TISS, Th erapeutic Intervention Scoring System; PEEP, positive end-expiratory pressure.
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Table 7b. TISS 3-point items included in study III
TISS 3-point items Prevalence in the study 
population (%)
Central IV hyperalimentation (includes renal, cardiac, hepatic failure fl uid) 49
Chest tubes 24
IMV or assisted ventilation 71
CPAP 47
Concentrated K+ infusion via central catheter 75
Nasotracheal or orotracheal intubation 32
Complex metabolic balance (frequent intake and output) 93
Multiple ABG, bleeding and/or STAT studies (>4 shift ) 57
Frequent infusion of blood products (>5 units/24 h) 8
Vasoactive drug infusion (1 drug) 77
Continuous antiarrhythmic infusions 21
Cardioversion for arrhythmia (not defi brillation) 8
Hypothermia blanket 26
Acute digitalisation – within 48 h 11
Measurement of cardiac output by any method 34
Active diuresis for fl uid overload or cerebral oedema 72
Emergency thora-, para- and peri-cardiocenteses 7
Active anticoagulation (initial 48 h) 78
Coverage with more than 2 IV antibiotics 29
TISS, Th erapeutic Intervention Scoring System; IV, intravenous; IMV, intermittent mandatory ventilation; 
CPAP, continuous positive airway pressure; ABG, arterial blood gas; STAT, statim.
4.3 Sta  s  cal Analyses
Statistical analyses were performed using IBM SPSS Statistics for Mac, versions 22.0, 23.0 
and 24.0 (IBM Corp, Armonk, NY, USA), R: A Language and Environment for Statistical 
Computing (R-Foundation for Statistical Computing, Vienna, Austria) with ‘PredictABEL’ 
[210] and ‘pROC’ [211] packages, and Stata Statistical Soft ware for Mac OS (StataCorp LP, 
College Station, TX, USA).
Th e chi-squared test (two-tailed) was used for categorical univariate analyses. Most of 
the continuous data were highly skewed, thus necessitating the use of the Mann-Whitney 
U-test in the majority of calculations. Th e Student’s t-test was used for normally distributed 
data. Categorical data are presented as absolute numbers (percentages), continuous 
nonparametric data as medians [interquartile range (IQR)] and parametric data as means 
[standard deviations (SDs)], unless stated otherwise.
Several severity-of-illness models were developed using multivariate logistic 
regression to evaluate temporal changes in outcomes and to estimate the independent eff ect 
of treatment intensity and specifi c therapeutic interventions on hospital mortality (Table 
8). Furtherrmore, risk-adjusted mortality rates were calculated for each year as the ratio 
between the observed and predicted outcomes, thereby representing the outcome rate if 
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the patient case-mix remained identical over time (II). Th e performance of the case-mix 
adjusted models was assessed using discrimination [area under the receiver operating 
characteristic curve (AUC)] and calibration using the Hosmer-Lemeshow C statistic (II and 
IV) [212,213]. Th e diff erences in AUCs were estimated using the bootstrap-based test, and 
improvement in a model’s performance was defi ned as the diff erence in AUC (ΔAUC) with 
a corresponding p value of < 0.001 (III) [210,211,214–216]. Additionally, improvement to 
a customised model’s performance was estimated using the continuous net reclassifi cation 
improvement (NRI) [217,218]. Where applicable, the variance infl ation factor (VIFmax) was 
calculated to test for collinearity between the included predictor variables (II and III).
Associations between variables and categorical outcomes were determined using 
binary logistic regression analysis through calculation of the odds ratios (ORs) with 
95% confi dence intervals (CIs) (II–IV). Associations between explanatory variables and 
continuous dependent variables, such as costs, TISS scores and length of stay, were assessed 
through estimating the coeffi  cients of a multivariate linear regression (IV). Th e threshold 
for statistical signifi cance was determined as p-value < 0.001 (II, III) and < 0.05 (IV) 
depending on the size of the study populations.
All healthcare-associated costs were adjusted to the 2013 consumer price index (CPI) 
in Finland in euro (€) using the following formula (IV):
 
Cost-eff ectiveness was calculated as the sum of total healthcare-associated costs in the 
respective patient group divided by the number of survivors for ECPS and by the number of 
survivors with a favourable neurological outcome for ECPFN (eff ective costs per survivor 
with a favourable neurological outcome) within the respective group of patients. Due to the 




Table 8. Variables included in the baseline severity-of-illness models
Study II Study III Study IV
Age Age Age
Preadmission physical status* Preadmission physical status* Simplifi ed preadmission physical 
status 
(independent vs not 
independent)











APACHE III diagnosis class
(cardiological vs 
non-cardiological)
– Time to ROSC
SAPS II score
(admission type, cardiovascular 
and age points subtracted)
SAPS II score
(admission type, comorbidity 
and age points subtracted)
SAPS II score






Any severe chronic comorbidity 
according to APACHE II
Any severe chronic comorbid-
ity according to APACHE II or 
SAPS II
Any severe chronic comorbid-
ity according to APACHE II or 
SAPS II
APACHE, Acute Physiology and Chronic Health Evaluation; SAPS, Simplifi ed Acute Physiology Score; 
ROSC,  return of spontaneous circulation; SOFA, Sequential Organ Failure Assessment.
*A modifi ed World Health Organization/Eastern Cooperative Oncology Group (WHO/ECOG) 




5.1 Previous Publica  ons on Intensive Care Unit Cardiac Arrest (I)
Th e initial literature search identifi ed 794 citations; one article was manually included, and 
three articles were added via a cross-reference search. Aft er screening for exclusion and 
inclusion criteria, the study included eighteen original publications. Th e lowest quality 
assessment score was 6 and the highest was 16; nine publications received 10 or more 
points. Th e weighted kappa score showed only a fair (0.339) agreement between two initial 
reviewers.
 All of the studies were published between 1990 and 2013. Five studies were prospective; 
amongst these, three were prospective studies focused specifi cally on ICU-CA, one was 
based on a prospective ICU registry and one was based on a prospective resuscitation 
registry (‘Get with the Guidelines Registry’) [50,118,123,167,219]. Th e remaining consisted 
of retrospective and single-centre studies (Table 9) [18–20,120–122,220–226].
 CA was uniformly defi ned as the cessation of circulatory function resulting in the 
initiation of CPR. Th e aetiology of ICU-CA varied from cardiac to septic with no obvious 
pattern, although only six studies reported aetiology-related data. According to thirteen 
studies reporting initial cardiac rhythms, in 55% to 84% of cases the initial cardiac rhythm 
was non-shockable. Th e time to the initiation of CPR was under 30 seconds [18,19]. In 
eleven studies the reported time to ROSC varied for hospital survivors from 5 to 65 minutes. 
Furthermore, ICU-CA incidence ranged from 6 to 78 per 1000 ICU admissions (Table 9). 
Initial survival (≥24 h) fell between 9% and 90%, whilst hospital survival varied from 0% to 
79%. Post-cardiac surgery patients exhibited the highest rate of hospital survival, although 
one of the two studies on post-cardiac surgery ICU-CA excluded patients with maximum 
inotropic support, intra-aortic balloon pump and ventricular assistant devices. For 
neurosurgical patients, survival to hospital discharge varied between 9% and 18% (Table 
9). Only nine studies reported data on long-term survival that spanned from 1% for ICU-
treated cancer patients up to 69% for cardiac surgery patients with a long-term follow-up 
period lasting from 6 months to 5 years. Finally, eleven studies mentioned ‘do not attempt 
resuscitation’ (DNAR) orders, whereby two studies included a clear description of the local 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.2 Intensive Care Unit Cardiac Arrest in Finland
5.2.1 Incidence of ICU-CA in Finnish intensive care units (II)
Between 2003 and 2013, 173,484 ICU admissions were registered in the FICC database. 
Of these, 8506 (5%) were excluded from the study as out-of-ICU-CAs. Th us, 164,255 ICU 
admissions were eligible for the incidence analysis. A CA event was documented in 4717 
cases, resulting in an overall incidence of 29 ICU-CAs per 1000 ICU admissions. Th e lowest 
incidence of ICU-CA occurred in the post-operative non-cardiovascular group, whilst 
the highest incidence was found in the non-operative cardiovascular group (Table 10). A 
signifi cant reduction in ICU-CA incidence occurred during the study period (Figure 1).
Table 10. ICU-CA incidence by APACHE III admission diagnosis group




Non-operative 3641 39 (37–40)
Cardiovascular and vascular 1414 118 (112–124)
Other non-operative 2227 27 (26–28)
Post-operative 1076 15 (15–16)
Cardiovascular   576 20 (19–22)
Other post-operative   500 12 (11–13)
Total 4717 29 (28–30)
ICU, intensive care unit; ICU-CA, in-ICU cardiac arrest; APACHE, Acute Physiology and Chronic Health 
Evaluation; CI, confi dence interval.
Results
Figure 1. ICU-CA incidence in Finnish ICUs reported as means and 95% confi dence intervals. 
ICU, intensive care unit; ICU-CA, in-ICU cardiac arrest. 
Figure adopted from Efendijev I, Intensive Care Med 2014;40:1853–61 with permission from 
Springer Nature®

























5.2.1.1 Incidence of ICU-CA in Meilahti Hospital ICUs (IV)
Between 2005 and 2013, 16,705 admissions were recorded in ICUs at Meilahti Hospital. 
Amongst these, 170 experienced an ICU-CA event, resulting in a crude ICU-CA incidence 
of 10/1000 ICU admissions.
5.2.2 Hospital mortality after ICU-CA in Finland (II)
To avoid classifying the same patient as dead or alive numerous times, mortality analyses 
required additional exclusion of all readmissions. Hence, amongst 164,255 ICU admissions 
eligible for the incidence analyses, 11,057 (6.7%) were excluded as readmissions. 
Additionally, 3681 (2.4%) admissions were excluded due to missing data. As a result, 149,517 
ICU admissions were eligible for mortality analyses. Of 4246 ICU-CA patients, 2355 (56%) 
did not survive to hospital discharge. Amongst non-CA patients (n = 145,271), a total of 
16,625 (11%) died during the same hospital stay. Compared to ICU-CA hospital survivors, 
ICU-CA hospital non-survivors were older, had more severe preadmission comorbidities, 
were more severely ill according to all implemented severity-of-illness scores (APACHE II, 
SAPS II and SOFA) and required more intensive treatment as demonstrated by the higher 
average daily TISS-76 score (Table 11).
Th e crude hospital mortality of post-cardiac surgery ICU-CA patients was 33%, 
whilst for the neurological/neurosurgical ICU-CA population the crude hospital mortality 
approached 56%. Th e adjusted severity-of-illness model showed satisfactory performance 
with AUC = 0.72 for ICU-CA patients and 0.85 for non-CA patients with no signifi cant 
collinearity between the predictors included (VIFmax = 3.331 for ICU-CA and VIFmax = 2.769 
for non-CA). Th e standardised mortality ratio was 1.00 (95% CI 0.97–1.03) and the risk-
adjusted mortality rate decreased signifi cantly over the study period for both ICU-CA and 
non-CA patients (Figures 2a and 2b). Over the study period, implementation of any type of 




Figure 2a. Adjusted mortality aft er ICU-CA in Finland, 2003-2013.
ICU, intensive care unit; ICU-CA, in-ICU cardiac arrest. 
Figure reprinted from Efendijev I, Intensive Care Med 2014;40:1853–61 with permission from 
Springer Nature®






Overall mortality = 56%
Adjusted mortality defined as the ratio between observed and predicted mortality times overall mortality for ICU-CA patients




















Overall mortality = 11%











Figure 2b. Adjusted mortality amongst non-CA ICU patients in Finland, 2003-2013.













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3 Cardiac Arrest Pa  ents in Meilah   Hospital ICUs
In total, 1343 ICU-treated CA patients were identifi ed, of whom 319 (24%) patients were 
excluded due to incomplete data. As a result, the fi nal study population consisted of 1024 
ICU-treated CA patients. Amongst these, 66% were OHCAs and 34% were IHCAs, 21% 
of whom experienced ICU-CAs. OHCA patients were younger, had a better functional 
status prior to ICU admission according to the simplifi ed WHO/ECOG classifi cation, 
fewer severe comorbidities and a lower severity of acute illness upon ICU admission. Th e 
initial cardiac rhythm was shockable for the majority of OHCAs, whilst it was either PEA 
or asystole for the majority of IHCA and ICU-CA patients. However, time to ROSC was 
considerably shorter for IHCAs and particularly for ICU-CAs (Table 12).
5.3.1 Survival and neurological outcome (IV)
One-year survival was 58% for OHCAs, 41% for IHCAs and 39% for ICU-CA patients. 
Amongst one-year survivors, 94% of OHCAs, 88% of IHCAs and 93% of ICU-CAs had 
CPC of 1 or 2. One-year survival did not change signifi cantly between 2005 and 2013, 
whilst the adjusted favourable neurological outcome improved over the study period for 
IHCA, but not for OHCA or ICU-CA.
5.3.2 Healthcare-associated costs (IV)
Th e total sum of healthcare-associated costs for all patients included in the study was 
€50,847,540. Hospital costs accounted for the majority of total costs (74%), followed by 
rehabilitation costs (14%) and social security costs (12%). Survivors with a favourable 
neurological outcome consumed 64% of all costs (over €32 million). Th e mean total costs 
were markedly higher for survivors compared to non-survivors and for survivors with an 
unfavourable outcome compared to survivors with a favourable outcome irrespective of the 
location of CA or the initial cardiac rhythm. Mean costs grouped by CA location and initial 
cardiac rhythm are presented in Figures 3 and 4, respectively.
Results
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Table 12. Baseline characteristics of the study population





Age in years, median (IQR) 61 (53–69) 64 (56–74) 64 (56–73)
Male sex, n (%) 514 (77) 231 (66) 50 (67)
Simplifi ed preadmission physical status*
Independent, n (%) 637 (95) 296 (84) 66 (88)
Non-independent, n (%) 35 (5) 56 (16) 9 (12)
Severe comorbidity at the time of ICU admission, n (%)** 92 (14) 125 (36) 29 (39)
SAPS II, median (IQR) 43 (34–57) 52 (39–68) 49 (38–66)
APACHE II score, median (IQR) 21 (17–29) 27 (19–34) 26 (18–32)
SOFA score during the fi rst 24 hours, median (IQR) 8 (6–10) 10 (8–13) 9 (7–13)
TISS-76 average daily score, mean (SD) 37 (8) 36 (9) 41 (9)
Time to ROSC in minutes, median (IQR) 20 (14–25) 7 (3–12) 3 (1–8)
Initial cardiac rhythm
Ventricular fi brillation/ventricular tachycardia, n (%) 504 (75) 116 (33) 29 (39)
Pulseless electrical activity 104 (15) 141 (40) 29 (39)
Asystole 49 (7) 66 (19) 10 (13)
Other/unknown 15 (2) 29 (8) 7 (9)
LOS ICU in days, median (IQR) 3 (2–4) 3 (1–6) 4 (2–11)
LOS hospital in days, median (IQR) 10 (4–19) 10 (4–20) 15 (5–29)
One-year survival, n (%) 391 (58) 146 (41) 29 (39)
One-year survival with a favourable neurological 
outcome, n (%) 367 (94) 128 (88) 27 (93)
OHCA, out-of-hospital cardiac arrest; IHCA, in-hospital cardiac arrest; ICU-CA, in-ICU cardiac arrest; 
IQR, interquartile range; ICU, intensive care unit; SD, standard deviation; SAPS, Simplifi ed Acute 
Physiology Score; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ 
Failure Assessment; TISS-76, Th erapeutic Intervention Scoring System 76; ROSC, return of spontaneous 
circulation; LOS, length of stay.
*A simplifi ed World Health Organization/Eastern Cooperative Oncology Group classifi cation.






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3.2.1 Factors infl uencing healthcare-associated costs in ICU-treated cardiac arrest 
patients
Based on the multivariate linear regression analyses, healthcare-associated costs decreased 
with asystole, an older age and a higher SAPS II score. For hospital survivors, the eff ect 
of asystole and an older age on healthcare-associated costs remained the same. However, 
a higher SAPS II score had an inverse eff ect on costs. An in-hospital CA and any severe 
preadmission comorbidity increased the total costs and some of its components. Th e most 
pronounced increase in the total costs resulted from the in-ICU CA location. Finally, the 
year of admission had no eff ect on healthcare-associated costs (Table 13 and Figure 5).
5.3.2.2 Cost-eff ectiveness
ECPS reached €94,688 whilst ECPFN was €102,722 for all patients. Th e highest eff ective 
costs emerged for the ICU-CA group, with ECPS of €239,468 and ECPFN of €257,207, 
followed by all IHCAs and OHCAs. When stratifi ed by initial cardiac rhythm, the eff ective 
costs were highest in the PEA group with ECPS of €94,688 and ECPFN of €106,555, whilst 
the eff ective costs for asystole and shockable rhythms remained comparable to one another 
(Figures 6 and 7).
5.3.2.3 Treatment intensity and length of stay
IHCA associated with a signifi cant increase in the case-mix adjusted treatment intensity 
expressed as the average daily TISS-76 score. Treatment intensity remained highest for the 
ICU-CA group and lowest for non-shockable rhythms and patients with a non-independent 
preadmission functional status.
Results























Patients with CPC 1–2
Figure 5. One-year total healthcare-associated costs for ICU-treated CA patients
ICU, intensive care unit; CA, cardiac arrest; CPC, Cerebral Performance Category.















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Whilst the case-mix adjusted length of ICU stay was longer for IHCAs, no diff erence 
was observed in the case-mix adjusted hospital length of stay between OHCAs and all 
IHCAs. Th e lengths of both ICU and hospital stays were signifi cantly longer for ICU-CA 
patients. Furthermore, the initial cardiac rhythm or time to ROSC did not infl uence 
the length of ICU stay, whilst the length of hospital stay decreased signifi cantly with an 
increase in time to ROSC. Dependency in self-care was associated with both longer ICU 
and hospital stays.
Results
Figure 6. Eff ective cost per one-year survivor (ECPS) and per survivor with favourable 
neurological outcome (ECPFN) stratifi ed by cardiac arrest location.
OHCA, out-of-hospital cardiac arrest; IHCA, in-hospital cardiac arrest; ICU-CA, in-ICU 
cardiac arrest.


























5.4 Treatment Intensity and Hospital Mortality in Finnish ICU 
Pa  ents
Amongst 173,484 ICU admissions identifi ed in the FICC database between 2003 and 
2013, a total of 42,493 were eligible for inclusion in this study. Th e remaining patients 
were excluded as readmissions, due to missing data or because the length of ICU stay was 
shorter than 3 days. In total, 34,009 (80%) survived to hospital discharge. According to 
the univariate analysis, hospital survivors were signifi cantly younger, less severely ill, were 
more likely capable of independent preadmission functioning (according to WHO/ECOG) 


























Figure 7. Eff ective cost per one-year survivor (ECPS) and per survivor with favourable 
neurological outcome (ECPFN) stratifi ed by initial cardiac rhythm.
VF/VT, ventricular fi brillation or ventricular tachycardia; PEA, pulseless electrical activity; 
ASY, asystole.
*patients with ‘other’ or unknown initial cardiac rhythm excluded (n=17).
**costs are adjusted to 2013 consumer price index in Finland in euro (€).
Figure adopted from Efendijev I, Resuscitation 2018;131:128–134 with permission from 
Elsevier®
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5.4.1 Association between TISS-76 scores and hospital mortality (III)
Th e average daily TISS-76 score revealed a signifi cant independent association with an 
increased risk of hospital mortality. Th is relationship was linear in the group of patients 
with a low initial risk of mortality estimated using traditional severity-of-illness scores. Any 
increase in treatment intensity (ΔTISS > 0) during the fi rst 3 days in ICU was observed for 
29% of patients and was associated with a marked increase in the risk of in-hospital death 
[adjusted OR 1.47 (95% CI 1.40–1.56)]. For those with a substantial increase in the early 
treatment intensity (ΔTISS ≥ 5), the risk of in-hospital death was even higher [adjusted OR 
1.74 (95% CI 1.63–1.87)].
Th e baseline prediction model (without TISS data) exhibited a satisfactory 
discrimination with AUC = 0.73 (95% CI 0.72–0.73). Adding the TISS scores to the baseline 
model improved the discrimination signifi cantly (ΔAUC 0.01–0.02, p < 0.001), whilst 
AUC increased further aft er adding selected TISS variables (ΔAUC = 0.03, p < 0.001). Th e 
increase to NRI was most notable in the low risk group (Table 14).
Table 14. Continuous NRI
TISS predictors added to 
the baseline risk model
Continuous NRI, %
All patients Risk group 1 Risk group 2 Risk group 3 Risk group 4
TISS D1 + ΔTISS 26 41 27 22 19
TISS AVG + ΔTISS 30 49 32 27 25
Select TISS items 41 55 49 38 29
NRI, net reclassifi cation improvement; TISS, Th erapeutic Intervention Scoring System 76; TISS D1, sum 
of TISS points on day 1; TISS AVG, mean daily TISS score for ICU stay; ΔTISS, diff erence between day 1 
and day 3.
Table adopted from Efendijev I, Acta Anaesthesiol Scand 2016;60:1415–24 with permission from John 
Wiley & Sons, Inc®.
5.4.2 Specific treatment interventions and hospital mortality (III)
From all 3- and 4-point TISS items, 11 individual and 2 combined items were included 
as candidate predictors. Amongst these, ‘cardiac arrest and/or countershock within 48 h’, 
‘haemodialysis in unstable patient’ and ‘major blood transfusion’ exhibited the strongest 
association with an increased risk of hospital death. A WHO/ECOG preadmission 
functional status “fully dependent” had a comparable eff ect on the risk of hospital mortality 
to that of the TISS item ‘cardiac arrest and/or countershock within 48 hours’, (see Figure 8). 





















































































































































































































































































































































































































6.1 ICU-CA in the Literature
According to the systematic review of the literature, the patient populations and settings 
of the published studies were quite heterogeneous. In-hospital Utstein guidelines fi rst 
appeared in 1997. Th us, most previous studies included in this literature review reported 
results inconsistently, thereby complicating comparisons, as indicated by the low kappa 
score. In general, the quality of the reviewed publications was limited, since most of the 
data on ICU-CA originated from single-centre retrospective studies.
As expected, the time to the initiation of CPR amongst ICU patients was short [18,19]. 
Most studies also reported time to ROSC, which stood at around 10 minutes for survivors 
and was noticeably longer for non-survivors. Although delays in the evaluation of the 
initial rhythm were virtually non-existent, the initial rhythm in the majority of ICU-CAs 
was non-shockable, indicative of a non-cardiac aetiology. Th is assumption was supported 
by the largest ICU-CA study, performed by Tian et al., according to which acute myocardial 
infarction represented the immediate reason for CA in only 9% of all cases [50].
Aetiology and predisposing clinical conditions also seem to aff ect ICU-CA outcomes. 
Circulatory insuffi  ciency before CA served as an apparent aggravating factor, since patients 
not on vasopressors at the time of arrest exhibited a higher likelihood of survival [50,224]. 
Furthermore, mortality rates appeared the lowest in post-cardiac surgery patients. In this 
patient population, CA oft en associated with a graft  malfunction-induced myocardial 
ischaemia, tamponade or ventricular tachyarrhythmia, all potentially straightforward and 
treatable clinical conditions given a prompt diagnosis and clear management protocols 
[118,121]. By contrast, patients from mixed and medical ICUs most likely present more 
complex CA aetiologies with multiple factors aff ecting post-ICU-CA survival. For instance, 
Wallace et al. reported the lowest hospital survival rate in the medical ICU of a comprehensive 
cancer centre, where only 2% of all ICU-CA patients survived to hospital discharge [20]. 
Interestingly, ICU-CA incidence (78/1000 ICU admissions) reported in the same study was 
5 to 10 times higher than reports from other studies [20,118,122,167,219,226].
Considerable diff erences in study populations, settings, local CA management and 
ICU admission policies might represent key factors aff ecting the observed variability in 
the ICU-CA incidence. Another, more recent systematic review of the literature and meta-
analysis on ICU-CA reported an incidence of ICU-CA of 5 to 78/1000 ICU admissions 
[227]. Th at study reports ICU-CA incidence estimates almost identical to the results from 
study I presented here, despite including a signifi cant number of more recent publications. 
However, aft er excluding studies with a high risk of selection bias, the pooled incidence of 
ICU-CA falls to 15/1000 ICU admissions. Th is fi gure is similar to the incidence rates found 
in study I aft er excluding the publication by Wallace et al [20].
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6.2 Cardiac Arrest Pa  ents in Finland
6.2.1 ICU-CA incidence and survival
Compared to earlier studies, an ICU-CA incidence of 29/1000 in Finnish ICUs appears 
somewhat high. However, a more recent registry-based study from the US (not included in 
the systematic review of the literature) reported an ICU-CA incidence of 18/1000, which 
is also higher than most previously published results [119]. As mentioned above, multiple 
factors including patient population, ICU admission criteria and DNAR policies can 
infl uence ICU-CA incidence. Additionally, the defi nition of CA adopted in study II may 
have overestimated ICU-CA incidence since, contrary to previous studies, ‘defi brillation 
only’ cases were also included in the analyses. However, ICU-CA incidence at Meilahti 
Hospital (10/1000 ICU admissions) was similar to earlier reports [227]. Th e discrepancy 
in ICU-CA incidence between study II and study IV can be explained by several factors. 
First, all ICUs at Meilahti Hospital staff  on-site physicians experienced in critical care at 
all times. Furthermore, all major medical specialties are available around the clock. Th us, 
severely ill and deteriorating ICU patients receive the necessary treatment with minimal 
delays, whilst potentially futile cases are identifi ed earlier and have DNAR orders sorted 
prior to further deterioration to CA. Finally, it is also possible that the ICU-CA incidence at 
Meilahti Hospital was underreported because the cardiosurgical ICU was not a member of 
FICC at the time of data collection. 
Hospital survival (44%) across all Finnish ICU-CA patients was comparable to 
two recent studies, but was signifi cantly higher than most previous reports [122,167]. 
Similar hospital survival rates (52%) were also observed among the Meilahti Hospital CA 
population. Based on the two substudies (II and IV) summarised here, hospital survival 
amongst Finnish ICU-CA patients was also signifi cantly higher than previously reported 
hospital survival (5–30%) for IHCA and hospital-treated OHCA patients. ICU patients 
remain under close and constant surveillance, which in turn leads to shorter delays in 
the initiation of CPR and, thus, possibly better outcomes. Depending on the institution’s 
DNAR policies, some ICU patients who continue to deteriorate despite adequate maximum 
organ support and approaching the complete exhaustion of physiological resources may 
not receive CPR upon acute cardiovascular collapse. Still, it is possible that some ICU-CA 
cases have an iatrogenic aetiology. Th ese might include profound hypotension or hypoxia 
due to the overzealous use of sedatives in connection with invasive therapeutic procedures 
or an acute cardiac arrhythmia during central venous cannulation from guidewire-induced 
excitation. In such cases, the initiating factor is clear and potentially amenable to treatment. 
At the same time, full ‘combat readiness’ amongst ICU staff  might lead to the prompt 
and possibly even proactive initiation of CPR and defi brillation. If a hypothetical ICU 
combines both features mentioned above, an increased incidence of ICU-CA may arise, 
simultaneously ‘preferring’ patients with a better prognosis and withholding CPR from 
patients with an evident poor outcome, thus improving local ICU-CA survival.
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6.2.2 Survival after OHCA and IHCA
Survival rates for OHCA and IHCA patients from Meilahti Hospital were higher compared 
to previous studies [102,110–114]. Th e patient population in study IV originates from the 
Hospital District of Helsinki and Uusimaa. Th e latter possesses a highly effi  cient emergency 
medical system (EMS) and has a high rate of bystander CPR. All patients included in 
study IV received post-arrest treatment in ICUs from a specialised cardiac arrest centre 
which staff s experienced intensivists and established post-arrest diagnostic and treatment 
procedures readily available around the clock. Additionally, study IV included strictly ICU-
treated CA patients. Th us, OHCA and non-ICU IHCAs with unsustained ROSC or those 
denied ICU admission due to a presumed poor outcome were excluded from analysis. Such 
an approach, in turn, could potentially overestimate survival rates. However, survival for 
the OHCA population in study IV was comparable to fi ndings reported in earlier Finnish 
studies on ICU-treated OHCAs [6,109].
6.2.3 Temporal trends in survival
Study II showed that both ICU-CA incidence and mortality have decreased in Finnish 
ICUs. However, the reason for such a decrease in nationwide ICU-CA incidence and 
mortality remains unclear. Interestingly, during the study period, the implementation of any 
type of treatment limitation signifi cantly increased. Additionally, the concept of medical 
emergency team (MET) was gradually adopted in Finnish hospitals during the study 
period, which in turn might have resulted in the earlier admission of deteriorating patients 
to ICUs and the more timely initiation of the appropriate treatment, thereby reducing both 
ICU-CA incidence and mortality over time. Furthermore, METs may have led to an earlier 
recognition of futile cases that would not benefi t from ICU admission. 
In the last decade, numerous publications also reported improvements in short-term 
survival for OHCA and IHCA [2,3,6,47,54,107,228,229], with at least one study reporting 
an improved one-year survival for OHCA patients [113]. Such temporal changes might, 
at least partially, occur due to an overall improvement in the ‘chain of survival’ [2,113]. 
However, study IV failed to identify any improvement in the one-year mortality amongst 
CA patients in the Meilahti Hospital population. Since the American Heart Association 
introduced the ‘chain of survival’ concept more widely in 1991, potentially by 2005 (the 
beginning of study IV), Helsinki’s EMS, local CPR training programmes for laypersons 
and in-hospital post-CA treatment were already quite mature [1]. Th is could have, in turn, 
diluted the temporal eff ect of improved peri-arrest treatment. Relatively high survival rates 
in the present study’s population might refl ect this, given that a similar situation was also 
previously observed in a diff erent population [230].
 Study II showed that hospital survival also improved for non-CA patients, suggesting 
that advancements in medical practices in the past decade, both inside and outside ICUs, 
might be responsible for the overall better survival of ICU patients generally and CA 
patients specifi cally. A more eff ective initial diagnostic and treatment approach along with 
the development of systematic treatment protocols could have resulted in better prevention 
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of the profound deterioration of a patient’s condition otherwise resulting in CA. Such 
practices could potentially reduce both incidence and mortality rates across all CA patients. 
Simultaneously, medicine continuously gains additional knowledge on the eff ectiveness 
and ineff ectiveness of certain treatment modalities in selected populations, thus improving 
clinicians’ understanding of specifi c medical situations, potentially reducing the number 
of futile eff orts and allowing for the redirection of precious resources towards patients 
most likely to benefi t from interventions. Th e observed increase in the implementation 
of any type of treatment limitations amongst Finnish ICU patients supports this view. 
Recently, a large study on ICU-treated CA patients from the UK reported a temporal 
increase in treatment withdrawal with a concurrent increase in the length of ICU stay, the 
time to treatment withdrawal and hospital survival rates [231]. Th e authors of that study 
suggested that the improved hospital survival of CA patients associates with prolonged ICU 
treatment and delayed decisions on treatment withdrawal. Th e nature of the relationship 
between treatment limitations and ICU-CA patient survival remains unclear. Perhaps, the 
more active implementation of DNAR orders would reduce ICU-CA incidence as well as 
ICU-CA mortality. However, the active adoption of DNAR policies should not result in the 
limitation of other appropriate medical treatments, since such practices that can potentially 
lead to worse functional outcomes in survivors [232].
6.2.4 Neurological outcomes
Several earlier publications reported prevalence rates for favourable neurological outcomes 
(CPC 1–2) amongst survivors of between 70% and 90%, rates similar to results from 
Meilahti Hospital. Notably, the rates for favourable neurological outcomes remained similar 
irrespective of CA location [48,50,60,109,111,117,122–125]. Such a remarkable similarity 
across diff erent studies relying on diff erent patient populations from diff erent geographic 
locations suggests that post-arrest treatment and prognostics practices are also similar. As 
a result, most CA survivors experience at least a satisfactory neurological and also possibly 
functional outcome. It is doubtful that such a similarity would occur by chance or simply 
by redirecting resources to patients perceived as having a better prognosis. Although based 
on speculation due to the absence of any fi rm scientifi c basis, it is possible that international 
resuscitation guidelines have infl uenced and unifi ed clinicians’ approaches to CA patients. 
However, it is also important to understand that CPC represents a robust and imprecise 
tool to assess neurological outcomes, and several studies have indicated that CPC might 
potentially overestimate positive outcomes [126–129]. Because neurological outcomes 
continue to improve for many months aft er CA, it is essential that comparisons between 
studies take measurements at equivalent time points.
6.2.5 Costs
Th e total costs reported in study IV consisted of an extensive dataset of direct costs 
alongside available indirect costs at one year aft er CA. Due to the lack of reliable data on 
survivors’ quality of life, the eff ective cost per ICU-treated post-CA survivor served as the 
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primary tool for the assessment of the economic impact of CA. Owing to the descriptive 
nature of the study, the aforementioned cost-eff ectiveness estimates did not require 
sensitivity analyses [188]. 
6.2.5.1 Previous studies
Data on CA-related healthcare costs remain scarce. Reported healthcare-associated costs 
amongst CA survivors vary between €36,000 and €50,000, and between €17,000 and 
€80,000 (expressed in 2013 euro) for survivors with a favourable neurological outcome 
[196,198,200,201,233]. Most previous studies included only in-hospital costs or pre- and 
in-hospital costs combined. Only one study reported post-discharge healthcare-associated 
costs of €36,600 in 2013 euro per 6-month OHCA survivor [199]. One study also reported 
ICU costs for ICU-CA hospital non-survivors [20]. Table 15 summarises the detailed 
characteristics of previous studies on CA-related healthcare costs.
According to previous studies, survival rates were generally lower than those reported 
here, although amongst ICU-treated CA patients survival rates were similar. Healthcare-
associated costs were higher in the present study, yet only one earlier study included data 
on post-discharge costs [199]. No earlier studies summarised comparable data on ICU-CA 
costs or the impact of peri-arrest factors on healthcare-associated costs and treatment 





























































































































































































































































































































































































































































































































































































































































































































6.2.5.2 Healthcare-associated costs and cardiac arrest location
Notably, IHCA associated with markedly higher total healthcare costs compared to OHCA. 
Th is association was even stronger for ICU-CA, a subgroup of the IHCA population that 
consumes a considerable amount of resources for every survivor, particularly for a survivor 
with a good neurological outcome. Th e observed increase in total costs for IHCA and 
ICU-CA patients primarily resulted from the increase in hospital costs, suggesting that 
hospital survivors have a similar long-term outcome and, thus, similar post-discharge 
healthcare utilisation irrespective of the location of the initial CA. Furthermore, in study 
IV, hospital costs for IHCA and ICU-CA may have included signifi cant pre-arrest expenses, 
thus overestimating total healthcare costs and particularly hospital costs. However, 67% of 
all IHCAs in this study experienced CA as early as on the fi rst day of hospital stay.
6.2.5.3 Healthcare-associated costs and initial cardiac rhythm
Asystole as the initial cardiac rhythm associated with a lower treatment intensity, 
a shorter length of ICU and hospital stays and signifi cantly lower total costs due to the 
reduced hospital and social security costs. Th ese fi ndings suggest that CA patients with 
an asystole as initial rhythm might require fewer resources possibly due to the diff erent 
arrest aetiologies, a higher risk of early mortality and perhaps a presumed poor outcome 
and less active treatment strategies. In clinical practice, PEA and asystole oft en receive 
similar treatment and are considered similar in terms of prognosis. Yet, study IV showed 
no defi nitive association between consumed resources and PEA.
6.2.5.4 Healthcare-associated costs, age and severity of illness
An increasing age and higher SAPS II scores associated with lower total healthcare-
associated costs, primarily due to lower hospital and social security costs. An inverse 
association between SAPS II scores and costs emerged when the analyses were repeated 
only amongst hospital survivors, suggesting an inverse U-shaped relationship between 
resource consumption and the severity of illness. Th e more severe the acute illness, the 
greater the need for resources until the severity of illness increases to a critical level, at 
which point further increases in the risk of early mortality result in a reduction in resource 
consumption. Interestingly, age had no infl uence on treatment intensity or length of ICU 
and hospital stays, whilst an increase in the SAPS II scores slightly reduced the TISS-76 
score and the length of the hospital stay, but exerted no eff ect on length of ICU stay.
6.2.5.5 Cardiac arrest-related healthcare costs in relation to other critical illnesses
As previously mentioned, in the United States in 2010, critical care medicine consumed 
US$108 billion or 0.7% of the US GDP [184]. Although the US healthcare system consumes 
the highest amount of resources in relation to GDP compared to other countries in the 
world and is not directly indicative of healthcare expenses in Finland, clearly critical care 
is resource-intensive [184,234]. According to Hamel and colleagues, the treatment costs of 
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high-risk comatose patients reached US$140,000 per QALY expressed in 1998 US dollars, 
or €221,000 in 2013 euro [235]. Amongst ICU patients treated for acute renal failure, the 
mean cost for one 6-month survivor was US$80,000 (expressed in 1993 US dollars), or 
€117,000 in 2013 euro [236]. Th e median total cost for a hospital survivor requiring acute 
renal replacement therapy reached €64,700 in 2013 euro [237]. For critically ill cancer 
patients, the costs per life gained ranged from US$82,845 to US$189,339 (expressed in 
US dollars, or €134,000–€305,000 in 2013 euro) [238]. For patients with a traumatic brain 
injury, the overall eff ective costs per 1-year survivor and per 1-year independent survivor 
were US$52,716 and US$83,533, respectively (expressed in 2013 US dollars, or €47,708 
and €75,595, respectively, in 2013 euro) [239]. Chin-Yee et al. reported ICU costs for 
very elderly (≥80 years) patients of CAD$61,783 per 1-year survivor (expressed in 2013 
Canadian dollars, or €46,453 in 2013 euro) [240]. Given these fi gures, the eff ective cost 
per one-year survivor with a favourable neurological outcome of €102,722 reported in this 
study does not seem particularly high, and appears lower than the generally accepted costs 
of other healthcare interventions [193,194,205]. However, the assessment of costs amongst 
critically ill patients remains a complex task and comparing studies may be biased by 
numerous pitfalls [188].
6.3 Associa  on Between Treatment Intensity and Hospital 
Mortality Amongst Finnish ICU Pa  ents
Th e creators of TISS initially recommended its use as a measure of the patient’s clinical 
condition [178]. TISS, a continuous activity-based scoring system, enjoys common 
use in documenting the daily eff orts required to care for critically ill patients. Th e score 
also indirectly refl ects the severity of the illness. Several earlier studies established a 
relationship between a higher risk for hospital mortality and higher TISS scores as a sign 
of premature ICU discharge [241–243]. Th e correlation between higher TISS scores and 
an unfavourable outcome was also previously noted in diff erent patient populations [244–
249]. Th is association itself seems quite logical, since the more severely ill a patient is the 
more interventions and resources he or she will consume unless a high early mortality 
reduces the need for additional resources. Nevertheless, using the TISS score to assess 
illness severity is complicated, since diff erent units and even diff erent clinicians will 
apply diff erent thresholds to implement specifi c supportive therapies. Th e present study 
showed that early TISS scores have an additional prognostic value as an early warning 
sign, particularly amongst patients with an initially low risk of mortality as predicted by 
conventional severity-of-illness scores. Hence, an activity-based score can bring additional 
value in the evaluation of mortality risk in settings where activity-based scores are already 
routinely collected. Yet, collecting activity-based scores can be quite burdensome. Th us, 
implementing such scores as a prognostic tool is probably not justifi ed if a scoring system 
is not already in use.
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According to the fi ndings presented here, specifi c TISS items also strongly individually 
associate with hospital mortality. Amongst these, the strongest association exists for hospital 
mortality and the TISS-76 item ‘cardiac arrest and/or countershock within 48 h’, with an 
eff ect size similar to a poor preadmission physical status. Whilst CA was not stratifi ed by 
location in this study, mortality and the incidence of IHCA, and ICU-CA in particular, 
will likely decrease through the development of more eff ective early warning and treatment 




Th e main limitation of the present study lies in its retrospective nature. Studies II through IV 
are registry-based, and, thus, prone to typical misclassifi cation and misinterpretation biases. 
Since the majority of ICU-CAs in study II stemmed from the non-operative cardiovascular 
group, it is possible that OHCA patients with APACHE III admission diagnoses other than 
CA but with a positive TISS-76 item for CA might have been classifi ed as ICU-CAs. Yet, 
this is probably quite uncommon in the FICC database due to its multilevel validation 
process. One should also note that whilst the highest hospital survival rate following 
ICU-CA emerged in the cardiac surgery population, this study did not include patients 
from Finland’s largest cardiac surgery ICU. Th e primary outcome of studies II and III lies 
in the hospital mortality–that is, not an optimal endpoint, given that many patients might 
be  discharged to other hospitals for further care potentially underestimating the mortality 
rates of the index hospitals. Furthermore, study I included articles published in English 
only. In addition, due to the signifi cant heterogeneity of the reviewed publications, a 
quantitative analysis of the data was omitted. In studies II through IV, 2% to 24% of patients 
had to be excluded due to missing data. Due to the retrospective nature of the study and the 
limitations of the data sources, separating pre-arrest expenses and resources for IHCA and 
ICU-CA patients in study IV remained impossible.
It is important to underscore that all relationships between individual variables and 
patient outcomes should be regarded as merely associative, since the study design and 
settings did not permit establishing causality between explanatory and dependent variables. 
Due to the lengthy study period, signifi cant changes in medical practices overall and in CA 




1) Th e incidence of ICU-CA in Finland appeared somewhat higher than that 
reported in the earlier literature, possibly due to diff erences in the defi nition of 
CA. Simultaneously, post-ICU-CA mortality appeared markedly lower whilst 
both incidence and mortality rates decreased during the ten years observed. 
Furthermore, one-year survival of ICU-treated CA patients generally improved 
from previous reports, whilst healthcare-associated costs were comparable to 
previous fi ndings. An in-hospital CA, especially ICU-CA, and PEA associated 
with signifi cantly higher healthcare costs.
2) An increase in early treatment intensity, expressed as a higher early TISS-76 score, 
associated with a higher risk of in-hospital death and can be used as an additional 
warning sign of a patient’s deterioration. Furthermore, CA associated with a 
signifi cant increase in the risk of in-hospital death with an eff ect-size comparable 




9.1 In-ICU Cardiac Arrest
Survival following ICU-CA appears better than in earlier reports, thus justifying more 
active treatment of ICU-CA patients. Furthermore, ICU-CA exhibits certain features that 
distinguish it from other IHCAs. Despite the existence of in-hospital Utstein guidelines, 
reporting of ICU-CA still lacks a unifi ed and systematic approach, indicating the need for 
both additional research and ICU-CA-focused reporting recommendations. Assuming 
that ICU-CA patients with an iatrogenic arrest aetiology will experience the best prognosis 
seems reasonable. Th is rationale, in turn, promotes the more active implementation of 
prevention strategies for high-risk procedures and patients. Such strategies should include 
procedural checklists and routine simulation-based training for ICU staff  [250,251].
9.2 Early Warning and Treatment Systems
Preventing IHCA through early recognition of deteriorating patients using either 
dichotomic MET criteria or early warning scores (EWS) serves as the foundation of 
contemporary rapid response systems [252,253]. Th e future development of more advanced 
monitoring systems for general ward patients–that is, continuous wireless monitoring with 
semi-automated alert systems guided by artifi cial intelligence–may potentially reduce the 
incidence of IHCA further. Such systems would allow for the identifi cation of deteriorating 
ward patients more eff ectively and timely, helping to prevent CA initially in hospitals and, 
in the more distant future, possibly even out-of-hospital [254–256]. Th is could potentially 
allow clinicians to intervene long before deterioration progresses to the ‘point of no return’. 
However, such systems also require a clear and well-defi ned DNAR policy. Th e latter, in 
turn, remains impossible without a proper understanding of the outcomes acceptable for 
patients themselves and for society.
9.3 Long-Term Outcomes and Costs
Numerous studies on CA report improvements in post-arrest survival. However, a better 
survival does not always equate with a better outcome [257]. In order to adequately assess 
post-CA patient outcomes, it is essential to obtain reliable data on the functional outcome 
and quality of life. Ideally, clinicians should also consider patients’ pre-arrest condition and 
the grade of disability acceptable for the patient. Post-CA functional outcomes and the 
quality of life continue to change for at least months aft er the initial arrest [130,131,258]. 
Future studies should concentrate on the identifi cation of precise and sensitive tools along 
with an accurate timing for the optimal assessment of post-CA patient outcomes [259].
More precise knowledge of post-arrest functional outcomes and CA-related healthcare 
costs might infl uence societal and medico-professional incentives, resulting in more 
eff ective prevention strategies. Th ese strategies might consist of the greater involvement 
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of laypersons as fi rst responders and improved management and rehabilitation strategies 
for CA victims. However, it should be stressed that treatment limitations and end-of-life 
decisions cannot be guided by economic concerns, but should be based on high-quality 
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